Upcoming Dividend • Jun 25
Upcoming dividend of zł0.08 per share Eligible shareholders must have bought the stock before 01 July 2026. Payment date: 20 August 2026. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 4.3%. Lower than top quartile of German dividend payers (4.8%). Higher than average of industry peers (2.5%). Reported Earnings • Jun 01
First quarter 2026 earnings released: EPS: zł0.046 (vs zł0.085 in 1Q 2025) First quarter 2026 results: EPS: zł0.046 (down from zł0.085 in 1Q 2025). Revenue: zł118.0m (down 3.8% from 1Q 2025). Net income: zł3.98m (down 47% from 1Q 2025). Profit margin: 3.4% (down from 6.1% in 1Q 2025). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 27% per year but the company’s share price has only increased by 4% per year, which means it is significantly lagging earnings growth. Declared Dividend • May 31
Dividend of zł0.08 announced Shareholders will receive a dividend of zł0.08. Ex-date: 1st July 2026 Payment date: 20th August 2026 Dividend yield will be 15%, which is higher than the industry average of 1.9%. Sustainability & Growth Dividend is covered by both earnings (36% earnings payout ratio) and cash flows (58% cash payout ratio). The dividend has decreased over the past 10 years, indicating a lack of growth and stability in payments. The company's earnings per share (EPS) would need to decline by 60% to shift the payout ratio to a potentially unsustainable range, which is more than the 7.2% EPS decline seen over the last 5 years. 공고 • May 27
Dr. Miele Cosmed Group S.A., Annual General Meeting, Jun 25, 2026 Dr. Miele Cosmed Group S.A., Annual General Meeting, Jun 25, 2026, at 10:00 Central European Standard Time. 공고 • Nov 06
Dr. Miele Cosmed Group S.A. to Report Q3, 2025 Results on Nov 06, 2025 Dr. Miele Cosmed Group S.A. announced that they will report Q3, 2025 results on Nov 06, 2025 Reported Earnings • Nov 10
Third quarter 2024 earnings released: EPS: zł0.14 (vs zł0.097 in 3Q 2023) Third quarter 2024 results: EPS: zł0.14 (up from zł0.097 in 3Q 2023). Revenue: zł131.9m (up 12% from 3Q 2023). Net income: zł12.1m (up 43% from 3Q 2023). Profit margin: 9.2% (up from 7.2% in 3Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has only increased by 2% per year, which means it is significantly lagging earnings growth. New Risk • Sep 26
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of German stocks, typically moving 7.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (7.0% average weekly change). Valuation Update With 7 Day Price Move • Sep 25
Investor sentiment improves as stock rises 23% After last week's 23% share price gain to €1.07, the stock trades at a trailing P/E ratio of 12x. Average trailing P/E is 21x in the Personal Products industry in Europe. Total returns to shareholders of 27% over the past three years. Reported Earnings • Sep 21
Second quarter 2024 earnings released: EPS: zł0.12 (vs zł0.06 in 2Q 2023) Second quarter 2024 results: EPS: zł0.12 (up from zł0.06 in 2Q 2023). Revenue: zł124.1m (up 14% from 2Q 2023). Net income: zł10.4m (up 99% from 2Q 2023). Profit margin: 8.4% (up from 4.8% in 2Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 22% per year but the company’s share price has only increased by 5% per year, which means it is significantly lagging earnings growth. Upcoming Dividend • Jun 25
Upcoming dividend of zł0.09 per share Eligible shareholders must have bought the stock before 02 July 2024. Payment date: 19 September 2024. Trailing yield: 2.6%. Lower than top quartile of German dividend payers (4.7%). Higher than average of industry peers (2.0%). 공고 • May 31
Dr. Miele Cosmed Group S.A., Annual General Meeting, Jun 25, 2024 Dr. Miele Cosmed Group S.A., Annual General Meeting, Jun 25, 2024. New Risk • May 05
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 8.0% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (8.0% increase in shares outstanding). Market cap is less than US$100m (€76.5m market cap, or US$82.4m). Reported Earnings • May 02
Full year 2023 earnings released: EPS: zł0.25 (vs zł0.026 loss in FY 2022) Full year 2023 results: EPS: zł0.25 (up from zł0.026 loss in FY 2022). Revenue: zł444.5m (up 12% from FY 2022). Net income: zł22.2m (up zł24.5m from FY 2022). Profit margin: 5.0% (up from net loss in FY 2022). The move to profitability was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings. Reported Earnings • Sep 20
Second quarter 2023 earnings released Second quarter 2023 results: Revenue: zł108.9m (up 13% from 2Q 2022). Net income: zł5.22m (up zł5.44m from 2Q 2022). Profit margin: 4.8% (up from net loss in 2Q 2022). The move to profitability was driven by higher revenue. New Risk • Jul 25
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of German stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (€54.2m market cap, or US$59.8m). Reported Earnings • Jun 05
First quarter 2023 earnings released First quarter 2023 results: Revenue: zł102.9m (up 20% from 1Q 2022). Net income: zł1.75m (up zł2.11m from 1Q 2022). Profit margin: 1.7% (up from net loss in 1Q 2022). The move to profitability was driven by higher revenue. 공고 • May 31
Global Cosmed S.A., Annual General Meeting, Jun 27, 2023 Global Cosmed S.A., Annual General Meeting, Jun 27, 2023, at 11:00 Central European Standard Time. Reported Earnings • Nov 19
Third quarter 2022 earnings released Third quarter 2022 results: Revenue: zł111.1m (up 26% from 3Q 2021). Net income: zł3.15m (down 15% from 3Q 2021). Profit margin: 2.8% (down from 4.2% in 3Q 2021). The decrease in margin was driven by higher expenses. Reported Earnings • Sep 21
Second quarter 2022 earnings released Second quarter 2022 results: Revenue: zł96.1m (up 14% from 2Q 2021). Net loss: zł220.0k (down 112% from profit in 2Q 2021). Reported Earnings • Jun 02
First quarter 2022 earnings released First quarter 2022 results: Revenue: zł86.1m (flat on 1Q 2021). Net loss: zł359.0k (down 108% from profit in 1Q 2021). 공고 • May 27
Global Cosmed S.A., Annual General Meeting, Jun 22, 2022 Global Cosmed S.A., Annual General Meeting, Jun 22, 2022, at 11:00 Central European Standard Time. Reported Earnings • Apr 21
Full year 2021 earnings released: EPS: zł0.13 (vs zł0.33 in FY 2020) Full year 2021 results: EPS: zł0.13 (down from zł0.33 in FY 2020). Revenue: zł351.9m (down 3.5% from FY 2020). Net income: zł11.6m (down 60% from FY 2020). Profit margin: 3.3% (down from 7.8% in FY 2020). The decrease in margin was primarily driven by lower revenue. Reported Earnings • Nov 10
Third quarter 2021 earnings released The company reported a poor third quarter result with weaker earnings, revenues and profit margins. Third quarter 2021 results: Revenue: zł88.5m (down 3.0% from 3Q 2020). Net income: zł3.73m (down 35% from 3Q 2020). Profit margin: 4.2% (down from 6.2% in 3Q 2020). Reported Earnings • Sep 15
Second quarter 2021 earnings released The company reported a poor second quarter result with weaker earnings, revenues and profit margins. Second quarter 2021 results: Revenue: zł84.5m (down 7.3% from 2Q 2020). Net income: zł1.86m (down 79% from 2Q 2020). Profit margin: 2.2% (down from 9.8% in 2Q 2020). Valuation Update With 7 Day Price Move • Apr 20
Investor sentiment deteriorated over the past week After last week's 17% share price decline to zł1.04, the stock trades at a trailing P/E ratio of 22.6x. Average trailing P/E is 23x in the Personal Products industry in Europe.